Key result
SLE linked to qualitative platelet defects in ~57% of patients.
Cross-Sectional (n=50)
Answers are grounded in this paper and cite their sources.
Reveals qualitative platelet dysfunction linked to disease severity in systemic lupus erythematosus, indicating serum-mediated inhibition of clotting activity.
Platelet function and coagulation profile were examined in 50 patients with systemic lupus erythematosus. A qualitative platelet defect was found in 12 of 21 consecutive patients tested, which consisted of absent collagen-induced aggregation and impaired ADP- and epinephrine-induced aggregation (nonresponder group). Impaired platelet function correlated with clinical severity of disease and seemed to result from an antiplatelet function factor(s) that was (were) detectable in the serum of three of seven patients tested in the nonresponder group. None of the four patients tested in the responder group had the factor(s). The coagulation profile done in 50 patients showed a circulating anticoagulant in three patients, elevated fibrinogen degradation products in five other patients, and nonspecific isolated abnormal findings in seven patients. Two of the circulating anticoagulants were identified as IgG and IgG + IgM immunoglobulins.
No takes yet. Share an insight, caveat, or question.
Martha G. Regan (1974) conducted a cross-sectional in Systemic lupus erythematosus (n=50). Systemic lupus erythematosus was evaluated on Qualitative platelet defect (absent collagen-induced and impaired ADP/epinephrine-induced aggregation). Systemic lupus erythematosus was associated with a qualitative platelet defect in 57.1% (12/21) of tested patients and a circulating anticoagulant in 6% (3/50).
Synapse has enriched 10 related papers. Consider them for comparative context: